Trial · NCT07879625
Effects of Injection Combined With Spencer Technique on Painful Frozen Shoulder
NCT07879625, Not applicable, Active not recruiting, Zichao Zhang
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Injection Combined With Spencer Technique on Painful Frozen Shoulder. Trials, record NCT07879625. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07879625
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Injection Combined With Spencer Technique on Painful Frozen Shoulder
- NCT number
- NCT07879625
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 64 participants, actual
- Lead sponsor
- Zichao Zhang
- Conditions
- Frozen Shoulder
- Interventions
- Ultrasound-guided injection of sodium hyaluronate, ropivacaine hydrochloride, and compound betamethasone, spencer, conventional rehabilitation
- First posted
- 2026-10-19
- Last updated
- 2026-11-05
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Constant-Murley score | CMS was administered at baseline, 8 weeks, 24 weeks. | Constant-Murley score, full name Constant-Murley Shoulder Score, ranges from 0 to 100, and a higher score indicates better overall shoulder function. |
| Secondary | the 17-item Tampa Scale for Kinesiophobia | TSK-17 was administered at baseline, 8 weeks, 24 weeks. | TSK-17, full name Tampa Scale of Kinesiophobia-17, ranges from 17 to 68, and a higher score indicates worse kinesiophobia. |
| Secondary | Mental health-related quality | SF-36 was administered at baseline, 8 weeks, 24 weeks. | SF-36 MCS, full name 36-Item Short-Form Health Survey Mental Component Summary, ranges from 0 to 100, and a higher score indicates better mental-health-related quality of life. |
| Secondary | Active shoulder ROM | ROM was administered at baseline, 8 weeks, 24 weeks. | Active shoulder ROM, full name active shoulder range of motion (including flexion, abduction, external rotation, internal rotation), measured in degrees, and a higher value indicates greater shoulder mobility. |
| Secondary | the coracohumeral ligament (CHL) | CHL was administered at baseline, 8 weeks, 24 weeks. | CHL, full name coracohumeral ligament, measured in millimetres, and a higher thickness value indicates more severe soft-tissue fibrosis. |
| Secondary | the inferior glenohumeral capsule | IGHC was administered at baseline, 8 weeks, 24 weeks. | IGHC, full name inferior glenohumeral capsule, measured in millimetres, and a higher thickness value indicates more severe capsular fibrosis. |
| Secondary | numeric rating scale | NRS was administered at baseline, 8 weeks, 24 weeks. | NRS, full name Numerical Rating Scale, rated from 0 to 10, and a higher score value indicates greater pain intensity. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07879625
GET https://conductscience.org/api/trials/v1/NCT07879625/registered